These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 8993358)

  • 1. Antibody responses of rats and humans to flagella-less cells and OspA protein of Borrelia burgdorferi.
    Sadziene A; Thompson PA; Barbour AG
    Ann N Y Acad Sci; 1996 Oct; 797():140-50. PubMed ID: 8993358
    [No Abstract]   [Full Text] [Related]  

  • 2. An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi.
    Luke CJ; Carner K; Liang X; Barbour AG
    J Infect Dis; 1997 Jan; 175(1):91-7. PubMed ID: 8985201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasmid DNA and protein vaccination of mice to the outer surface protein A of Borrelia burgdorferi leads to induction of T helper cells with specificity for a major epitope and augmentation of protective IgG antibodies in vivo.
    Zhong W; Wiesmüller KH; Kramer MD; Wallich R; Simon MM
    Eur J Immunol; 1996 Nov; 26(11):2749-57. PubMed ID: 8921965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral delivery of purified lipoprotein OspA protects mice from systemic infection with Borrelia burgdorferi.
    Luke CJ; Huebner RC; Kasmiersky V; Barbour AG
    Vaccine; 1997; 15(6-7):739-46. PubMed ID: 9178476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of recombinant Bacille Calmette-Guérin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine.
    Edelman R; Palmer K; Russ KG; Secrest HP; Becker JA; Bodison SA; Perry JG; Sills AR; Barbour AG; Luke CJ; Hanson MS; Stover CK; Burlein JE; Bansal GP; Connor EM; Koenig S
    Vaccine; 1999 Feb; 17(7-8):904-14. PubMed ID: 10067697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of multiple reactive protein species by immunoblotting after recombinant outer surface protein A lyme disease vaccination.
    Molloy PJ; Berardi VP; Persing DH; Sigal LH
    Clin Infect Dis; 2000 Jul; 31(1):42-7. PubMed ID: 10913394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the saponin adjuvant QS-21 and aluminium hydroxide on the immunogenicity of recombinant OspA and OspB of Borrelia burgdorferi.
    Ma J; Bulger PA; Davis DR; Perilli-Palmer B; Bedore DA; Kensil CR; Young EM; Hung CH; Seals JR; Pavia CS
    Vaccine; 1994 Aug; 12(10):925-32. PubMed ID: 7975834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of immunization with recombinant OspA on serologic tests for Lyme borreliosis.
    Fawcett PT; Rose CD; Budd SM; Gibney KM
    Clin Diagn Lab Immunol; 2001 Jan; 8(1):79-84. PubMed ID: 11139199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective immunity elicited by rBCG vaccines.
    Stover CK; Bansal GP; Langerman S; Hanson MS
    Dev Biol Stand; 1994; 82():163-70. PubMed ID: 7958471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the production of anti-OspA borreliacidal antibody with T cells from hamsters vaccinated against Borrelia burgdorferi.
    Jensen JR; Du Chateau BK; Munson EL; Callister SM; Schell RF
    Infect Immun; 1998 Apr; 66(4):1507-12. PubMed ID: 9529074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production of borreliacidal antibody to outer surface protein A in vitro and modulation by interleukin-4.
    Munson EL; Du Chateau BK; Jobe DA; Lovrich SD; Callister SM; Schell RF
    Infect Immun; 2000 Oct; 68(10):5496-501. PubMed ID: 10992445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of Lyme disease after OspA vaccine.
    Schutzer SE; Luan J; Coyle PK
    N Engl J Med; 1997 Sep; 337(11):794-5. PubMed ID: 9289653
    [No Abstract]   [Full Text] [Related]  

  • 13. Growth-inhibiting antibody responses of humans vaccinated with recombinant outer surface protein A or infected with Borrelia burgdorferi or both.
    Luke CJ; Marshall MA; Zahradnik JM; Bybel M; Menefee BE; Barbour AG
    J Infect Dis; 2000 Mar; 181(3):1062-8. PubMed ID: 10720532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine.
    Stover CK; Bansal GP; Hanson MS; Burlein JE; Palaszynski SR; Young JF; Koenig S; Young DB; Sadziene A; Barbour AG
    J Exp Med; 1993 Jul; 178(1):197-209. PubMed ID: 8315378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Killing of Borrelia burgdorferi by antibody elicited by OspA vaccine is inefficient in the absence of complement.
    Nowling JM; Philipp MT
    Infect Immun; 1999 Jan; 67(1):443-5. PubMed ID: 9864253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The recombinant outer surface protein A (lipOspA) of Borrelia burgdorferi: a Lyme disease vaccine.
    Wallich R; Kramer MD; Simon MM
    Infection; 1996; 24(5):396-7. PubMed ID: 8923055
    [No Abstract]   [Full Text] [Related]  

  • 17. DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme disease.
    Wallich R; Siebers A; Jahraus O; Brenner C; Stehle T; Simon MM
    Infect Immun; 2001 Apr; 69(4):2130-6. PubMed ID: 11254567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of an outer surface protein A vaccine in subjects with previous Lyme disease.
    Schoen RT; Meurice F; Brunet CM; Cretella S; Krause DS; Craft JE; Fikrig E
    J Infect Dis; 1995 Nov; 172(5):1324-9. PubMed ID: 7594671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Borrelia burgdorferi escape mutants that survive in the presence of antiserum to the OspA vaccine are killed when complement is also present.
    Solé M; Bantar C; Indest K; Gu Y; Ramamoorthy R; Coughlin R; Philipp MT
    Infect Immun; 1998 Jun; 66(6):2540-6. PubMed ID: 9596714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of canine humoral immune responses to outer surface protein subunit vaccines and to natural infection by Lyme disease spirochetes.
    Ma J; Bulger PA; Dante S; Davis DR; Perilli-Palmer B; Coughlin RT
    J Infect Dis; 1995 Apr; 171(4):909-15. PubMed ID: 7706819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.